Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Watching Expion360; Zacks Small-Cap Research Sets $4.25 Price Valuation

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_01302023_XPON_Lantier.pdf
byHappy Mohamed
January 30, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_01302023_XPON_Lantier.pdf

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Regeneron Pharmaceuticals Announced Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH 2022

By Charles Gross
December 11, 11:34 AM
- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new and updated data from a Phase 1 and pivotal Phase 2 trial (ELM-1 and ELM-2) evaluating investigational odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

REGN